Form 4: Processa Pharmaceuticals Grants Over 1.8 Million Restricted Stock Units to R&D President David Young

Processa Pharmaceuticals, Inc. has granted 1,813,133 restricted stock units to David Young, President of Research & Development, with vesting scheduled through January 2028 and a portion contingent on stockholder approval.

Summary

• David Young, President of Research & Development and a Director at Processa Pharmaceuticals, Inc. (PCSA), was granted 1,813,133 Restricted Stock Units (RSUs).
• The transaction date for this grant was July 24, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in a staggered manner: one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.
• A significant portion, 1,790,833 shares, is subject to stockholder approval of the revised Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan.
• Following this transaction, David Young beneficially owns 1,821,016 derivative securities.
• The RSUs were granted at a price of $0, which is typical for such equity compensation.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the grant represents potential future dilution, it primarily serves to align the interests of a key executive with shareholders and incentivize long-term performance, which is generally viewed favorably. The contingency on stockholder approval adds a minor element of uncertainty.

Positives

• The grant of Restricted Stock Units to the President of Research & Development aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule over several years (until January 2028) promotes long-term commitment from a key executive.

Negatives

• The grant of 1,813,133 RSUs represents potential future dilution for existing shareholders upon vesting.
• A substantial portion of the grant (1,790,833 shares) is contingent on future stockholder approval of a revised incentive plan, introducing a degree of uncertainty.

Risks

• The grant of 1,790,833 shares is subject to stockholder approval of the revised 2019 Omnibus Incentive Plan; failure to obtain this approval could impact the executive's compensation and retention.
• Future dilution from the vesting of these RSUs could impact earnings per share and stock price.

Future Outlook

The future outlook indicates a long-term incentive structure for the President of Research & Development, with vesting of the granted Restricted Stock Units scheduled to occur incrementally from January 1, 2026, through January 1, 2028. A significant portion of these units is contingent on future stockholder approval of a revised incentive plan.

Industry Context

This RSU grant is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key scientific and executive talent, aligning their interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• Equity compensation, such as Restricted Stock Units, is a common component of executive compensation packages across the pharmaceutical and biotech sectors, comparable to practices at companies like BioNTech, Moderna, or smaller clinical-stage biotechs, which often use such grants to retain talent in a highly competitive industry.
• The multi-year vesting schedule is typical for long-term incentive plans, similar to those observed in peer companies to ensure sustained executive commitment.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to David Young, a Director and President of Research & Development, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of RSUs, but also benefit from incentivized executive performance and retention.
• Employees: May view this as a positive signal regarding executive commitment and the company's long-term prospects, potentially influencing morale and retention.
• Management: David Young's compensation is significantly tied to the company's long-term stock performance, aligning his financial interests with company growth.

Next Steps

• Stockholders will need to vote on the approval of the revised 2019 Omnibus Incentive Plan, which affects 1,790,833 of the granted RSUs.
• The first tranche of RSUs will vest on January 1, 2026.
• Subsequent monthly vesting will occur until full vesting on January 1, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive. While it aligns management incentives, it does not provide new fundamental information about the company's financial performance, strategic direction, or operational milestones that would warrant a change in investment recommendation. It is a standard disclosure of an insider transaction.

Keywords

Processa Pharmaceuticals, PCSA, Restricted Stock Units, RSU grant, executive compensation, insider transaction, equity incentive plan, stockholder approval, Form 4, David Young